IL156910A0 - Isolating cells expressing secreted proteins - Google Patents

Isolating cells expressing secreted proteins

Info

Publication number
IL156910A0
IL156910A0 IL15691002A IL15691002A IL156910A0 IL 156910 A0 IL156910 A0 IL 156910A0 IL 15691002 A IL15691002 A IL 15691002A IL 15691002 A IL15691002 A IL 15691002A IL 156910 A0 IL156910 A0 IL 156910A0
Authority
IL
Israel
Prior art keywords
poi
isolating cells
cells expressing
secreted proteins
expressing secreted
Prior art date
Application number
IL15691002A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL156910A0 publication Critical patent/IL156910A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL15691002A 2001-01-16 2002-01-16 Isolating cells expressing secreted proteins IL156910A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26199901P 2001-01-16 2001-01-16
PCT/US2002/001208 WO2002057423A2 (fr) 2001-01-16 2002-01-16 Isolement de cellules exprimant des protéines sécrétées

Publications (1)

Publication Number Publication Date
IL156910A0 true IL156910A0 (en) 2004-02-08

Family

ID=22995765

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15691002A IL156910A0 (en) 2001-01-16 2002-01-16 Isolating cells expressing secreted proteins
IL156910A IL156910A (en) 2001-01-16 2003-07-14 Method of detecting and isolating eukaryotic cell that produces secreted protein of interest

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156910A IL156910A (en) 2001-01-16 2003-07-14 Method of detecting and isolating eukaryotic cell that produces secreted protein of interest

Country Status (10)

Country Link
US (3) US6919183B2 (fr)
EP (1) EP1392859B1 (fr)
JP (1) JP4323167B2 (fr)
AT (1) ATE325865T1 (fr)
AU (1) AU2002245272B2 (fr)
CA (1) CA2434802C (fr)
DE (1) DE60211329T2 (fr)
HK (1) HK1059290A1 (fr)
IL (2) IL156910A0 (fr)
WO (1) WO2002057423A2 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
DE60211329T2 (de) * 2001-01-16 2007-05-24 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen
GB0118337D0 (en) * 2001-07-27 2001-09-19 Lonza Biologics Plc Method for selecting antibody expressing cells
US20050221325A1 (en) * 2002-05-22 2005-10-06 Greg Thill Detection of secreted polypeptides
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
EP1658498A1 (fr) * 2003-08-20 2006-05-24 Celltech R & D Limited Methodes de production d'anticorps
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
WO2007130520A2 (fr) 2006-05-04 2007-11-15 Abmaxis Inc. Systèmes d'expression à la surface multispécifique et hétérospécifique
ES2573027T3 (es) 2006-05-17 2016-06-03 F. Hoffmann-La Roche Ag Células productoras de polipéptido
CA2671264C (fr) * 2006-11-30 2015-11-24 Research Development Foundation Bibliotheques d'immunoglobulines ameliorees
WO2008103474A1 (fr) 2007-02-20 2008-08-28 Anaptysbio, Inc. Procédés de production de pharmacothèques, et leurs utilisations
EP2617827A1 (fr) * 2007-03-26 2013-07-24 Celexion, LLC Affichage de surface cellulaire, criblage et production de protéines d'intérêt
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
AU2008340053A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as PI 3 kinase inhibitors
WO2009103753A1 (fr) * 2008-02-20 2009-08-27 Ablynx Nv Procédés d'identification et/ou de tri de cellules par molécule sécrétée et coffrets pour la mise en œuvre de tels procédés
JP5731827B2 (ja) * 2008-03-03 2015-06-10 グライコフィ， インコーポレイテッド 下等真核生物中での組換えタンパク質の表面ディスプレイ
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
CN102239183B (zh) * 2008-12-04 2017-06-30 韩国生命工学研究院 大量分泌的蛋白的筛选和它们作为融合配偶体在重组蛋白制备中应用
DK2438171T3 (en) 2009-06-02 2015-01-26 Regeneron Pharma Fucosylerings-deficient cells
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8278873B2 (en) * 2009-09-10 2012-10-02 Syntheon, Llc Surgical sterilizer with integrated battery charging device
MX2012009175A (es) * 2010-02-12 2012-12-17 Oncomed Pharm Inc Metodos para identificar y aislar celulas que expresan un polipeptido.
EP2390661B1 (fr) * 2010-05-02 2015-06-24 Miltenyi Biotec GmbH Supports d'ancrage/capture pour sélectionner ou analyser une cellule CHO en fonction d'un produit sécrété par la cellule CHO
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP2593594B1 (fr) 2010-07-16 2017-09-27 Adimab, LLC Banques d'anticorps
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
WO2012060666A2 (fr) 2010-11-04 2012-05-10 한국생명공학연구원 Procédé de production à grande échelle de facteur de croissance épidermique humain à partir de levures
IL210093A0 (en) * 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
EP2658971A1 (fr) 2010-12-28 2013-11-06 XOMA Technology Ltd. Présentation sur surface cellulaire utilisant des domaines pdz
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
CN102680679B (zh) * 2011-03-15 2014-08-27 中国科学院上海生命科学研究院 检测单细胞特异性抗体分泌的细胞微孔芯片及其制备方法
WO2013061305A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Nouveaux dérivés de purine et utilisation de ceux-ci dans le traitement d'une maladie
CN104271816A (zh) 2012-05-11 2015-01-07 默沙东公司 表面锚定的轻链诱饵抗体展示系统
EP2849756A1 (fr) 2012-05-16 2015-03-25 Novartis AG Régime posologique pour un inhibiteur de pi-3 kinase
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2888283B1 (fr) 2012-08-24 2018-09-19 The Regents of The University of California Anticorps et vaccins utilisables en vue du traitement de cancers ror1 et de l'inhibition de la métastase
TW202423993A (zh) * 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
EP2970415B1 (fr) 2013-03-14 2018-12-19 Regeneron Pharmaceuticals, Inc. Protéines de fusion d'apéline et leurs utilisations
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
MX2016004564A (es) 2013-10-11 2016-07-12 Regeneron Pharma Cultivo celular metabolicamente optimizado.
KR20160095035A (ko) 2013-12-06 2016-08-10 노파르티스 아게 알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
JP2018532750A (ja) 2015-11-02 2018-11-08 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
WO2017132701A1 (fr) * 2016-01-31 2017-08-03 Shuang Zhang Procédé de criblage d'anticorps
AU2017213633B2 (en) 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
EP3464332A1 (fr) 2016-05-26 2019-04-10 University College Cork - National University of Ireland, Cork Procédés pour améliorer la prolifération de cellules mammaliennes
WO2017203051A1 (fr) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork Bactérie gram positif modifiée
WO2018005519A2 (fr) 2016-06-27 2018-01-04 The Regents Of The University Of California Associations médicamenteuses pour le traitement du cancer
WO2018041740A1 (fr) 2016-09-01 2018-03-08 Bayer Pharma Aktiengesellschaft Système d'affichage non covalent à l'aide de fimgt/dsf
WO2018060833A1 (fr) 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
CN109790214B (zh) 2016-09-29 2022-09-06 豪夫迈·罗氏有限公司 用于选择产生多肽的细胞的改进方法
GB201703418D0 (en) 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
GB201704115D0 (en) * 2017-03-15 2017-04-26 Oxford Genetics Ltd Method of selecting for antibodies
SG10202110530WA (en) * 2017-03-24 2021-11-29 Lankenau Inst Medical Res Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
US11833178B2 (en) 2017-08-25 2023-12-05 University College Cork—National University of Ireland, Cork Bifidobacterium longum for treating obesity and weight management
US20200345051A1 (en) 2017-11-24 2020-11-05 University College Cork, National University Of Ireland, Cork A composition comprising a cohort of bacteria
EP3604507A1 (fr) 2018-07-30 2020-02-05 University College Cork-National University of Ireland, Cork Enzyme oméga-transaminase
US20230212237A1 (en) * 2018-09-17 2023-07-06 South Australian Health And Medical Research Institute Limited Methods for producing proteins
SG11202108451VA (en) * 2019-04-03 2021-09-29 Regeneron Pharma Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
EP3783012A1 (fr) 2019-08-20 2021-02-24 Nuritas Limited Peptide antimicrobien
JP2022545265A (ja) 2019-08-20 2022-10-26 ニューリタス リミテッド 筋萎縮を治療するためのペプチド
MX2022004872A (es) 2019-10-22 2022-05-13 Nuritas Ltd Tratamiento de enfermedad de higado graso no alcoholico.
WO2022190733A1 (fr) * 2021-03-10 2022-09-15 ソニーグループ株式会社 Procédé d'analyse de particules biologiques, et kit de réactifs pour analyse de particules biologiques
EP4070670A1 (fr) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 et ses utilisations
JP2024514195A (ja) 2021-04-14 2024-03-28 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 脳血管イベントおよび神経障害の治療
CA3214579A1 (fr) 2021-04-14 2022-10-20 Tom Moore Psg1 destinee a etre utilisee dans le traitement de l'arthrose
IL311248A (en) 2021-10-07 2024-05-01 Regeneron Pharma PH meter calibration and repair
WO2023059800A2 (fr) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systèmes et méthodes de modélisation et de régulation du ph
WO2023167863A1 (fr) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Procédé de fabrication d'anticorps à titre élevé
WO2024078729A1 (fr) 2022-10-14 2024-04-18 University College Cork - National University Of Ireland, Cork Protéines exprimées par le placenta pour utilisation dans le traitement d'une lésion d'un tendon
CN118006552A (zh) * 2024-04-09 2024-05-10 暨南大学 一种抗原特异性浆细胞的筛选方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009117A1 (fr) * 1992-10-21 1994-04-28 Miltenyi Biotec Inc Selection directe de cellules par un produit de secretion
US6287784B1 (en) * 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
NZ512006A (en) * 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
DE69941150D1 (de) * 1998-05-11 2009-09-03 Miltenyi Biotec Gmbh Verfahren zur direkten auswahl von antigen-spezifischen t-zellen
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
DE19900635A1 (de) * 1999-01-11 2000-07-13 Deutsches Krebsforsch Selektion von monoklonalen Antikörpern
DE60211329T2 (de) * 2001-01-16 2007-05-24 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen

Also Published As

Publication number Publication date
DE60211329D1 (de) 2006-06-14
CA2434802C (fr) 2013-05-28
EP1392859A4 (fr) 2004-11-24
ATE325865T1 (de) 2006-06-15
IL156910A (en) 2009-08-03
HK1059290A1 (en) 2004-06-25
JP2004520037A (ja) 2004-07-08
DE60211329T2 (de) 2007-05-24
WO2002057423A3 (fr) 2003-12-18
AU2002245272B2 (en) 2006-06-29
US20060234311A1 (en) 2006-10-19
US7435553B2 (en) 2008-10-14
EP1392859B1 (fr) 2006-05-10
US20050186623A1 (en) 2005-08-25
WO2002057423A2 (fr) 2002-07-25
US20020168702A1 (en) 2002-11-14
JP4323167B2 (ja) 2009-09-02
US6919183B2 (en) 2005-07-19
EP1392859A2 (fr) 2004-03-03
CA2434802A1 (fr) 2002-07-25

Similar Documents

Publication Publication Date Title
IL156910A0 (en) Isolating cells expressing secreted proteins
WO2002034906A3 (fr) Procede pour l'exposition de peptides et de polypeptides sur la surface cellulaire de bacteries
WO2002079490A3 (fr) Codes-barres biologiques bases sur des particules a modification oligonucleotidique
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
WO2002004523A3 (fr) Polypeptides d'anticorps artificiels
EP1499885A4 (fr) Nouvelles proteines de fusion et analyses de detection de liaisons moleculaires
DK1410023T3 (da) Fremgangsmåder til anvendelse af 06-alkylguanin-DNA-alkyltransferaser
WO2006107813A3 (fr) Incorporation specifique a un site de phosphoserine dans des polypeptides a l'aide de la phosphoseryl-trna synthetase
DK1616878T3 (da) Udskilte og membranspændende polypeptider samt nukleinsyrer kodende for disse
WO2002086081A3 (fr) Procedes et systemes permettant d'identifier des proteines
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
WO2006127822A3 (fr) Polypeptides associes au domaine 1 de scytovirine
DK1576157T3 (da) Fluorescerende proteiner fra Copepode-arter og fremgangsmåder til anvendelse af samme
WO2003018797A3 (fr) Procede et dispositif destines a l'expression, la purification et la detection proteiques
WO2003016904A3 (fr) Etiquettes de sequence peptidique et leur procede d'utilisation
ATE310248T1 (de) Biomolekülanalyse auf array-basis
WO2002064747A3 (fr) Proteine de fusion avec recepteurs de la somatostatine
WO2003020005A3 (fr) Proteines de mammiferes lp et reactifs associes
WO2003062444A3 (fr) Systemes matriciels et procedes
WO2003033650A3 (fr) Systeme a base de renilla reniformis recombinee servant au transfert d'energie par resonance de bioluminescence
HUP0101987A2 (hu) Antibiotikus hatású proteinek és peptidek indukciója LAIT/sCD14-proteinnel
WO2005001099A3 (fr) Systeme d'expression de proteine
ATE307142T1 (de) Zweifarbiges fluorimetrisches proteaseassay
WO2002042458A3 (fr) Nouveaux recepteurs
WO2002074906A3 (fr) Proteines de mammiferes lp et reactifs associes